Development of a Quantitative Point of Care Salivary Testosterone Test

索马生物科学是一家研发型中小企业，需要扩大产品线以实现增长和生存。内分泌检测是一项快速发展的活动，以应对日益增长的肥胖和糖尿病，2014年全球市场估计为61亿美元，预计到2023年将达到128亿美元。唾液收集和分析已迅速发展成为一种评估通常在血液中测量的生物标志物的工具，其优点是无创，对参与者的压力较小，比静脉穿刺更便宜，需要的专业知识更少。护理点睾酮测试的发展是一种生物科学表征和发现工具，可以比传统但缓慢的血液实验室方法更快，更便宜的结果。该项目的新颖之处在于，没有实时测试来测量anaobolic激素，但与压力，疾病，幸福，性功能和运动科学领域的研究人员和临床医生有关。在医疗保健领域，这种工具与老龄化人口越来越相关。该项目旨在生产一种原型唾液睾酮Point of Care LF测试，在进入全面商业化和临床试验之前，可以立即作为研究工具产生收入。

Soma Bioscience is a R & D SME that needs to expand product lines to grow and survive. Endocrine testing is a rapidly developing activity in response to the growing prevavlence of obesity and diabetes, with the global market estimated at US$6.1 bn in 2014 and projected to reach $12.8 bn by 2023. Saliva collection and analysis has rapidly and recently developed as a tool for the assessment of biomarkers usually measured in blood and offers the advantage of being non-invasive, less stressful to participants, is cheaper and requiring less expertise than venipuncture. The development of a Point of Care testosterone test is a bioscience characterisation and discovery tool that would enable much quicker and cheaper results than traditional, yet slow, blood laboratory methods. The novel aspect of this project is that no real-time test to measure anaobolic hormones exists, yet is relevant to researchers and clinicians in the fields of stress, disease, well-being, sexual function and sport science. In the field of healthcare, such a tool is becoming more relevant to an ageing population. This project aims to produce a protoype salivary testosterone Point of Care LF test, that can generate revenue immediately as a research tool, before moving to full commercialisation and clinical trials.